Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
11 papers
Recent·Most cited
M. McCallum, Y.-J. Park, C. Stewart, K. R. Sprouse, J. Brown, M. A. Tortorici, C. Gibson, E. Wong, M. Ieven, A. Telenti, D. Veesler
This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.
Cell · Aug 1, 2024Peer-reviewedBiochemistry
A. Addetia, C. Stewart, A. J. Seo, K. R. Sprouse, A. Y. Asiri, M. Al-Mozaini, Z. A. Memish, A. Alshukairi, D. Veesler
This study maps immunodominant sites on MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans, showing peak neutralizing activity against S1 and RBD epitopes.
bioRxiv · Mar 31, 2024Immunology
M. Rexhepaj, Y.-J. Park, L. Perruzza, D. Asarnow, M. McCallum, K. Culap, C. Saliba, G. Leoni, A. Balmeli, C. Yoshiyama, M. S. Dickinson, J. Quispe, J. T. Brown, M. A. Tortorici, K. R. Sprouse, , D. Veesler
The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.
bioRxiv · Mar 27, 2024 · PreprintBiochemistry
C. W. Chao, K. R. Sprouse, M. C. Miranda, N. J. Catanzaro, M. L. Hubbard, A. Addetia, C. Stewart, J. T. Brown, A. Dosey, A. Valdez, R. Ravichandran, G. G. Hendricks, M. Ahlrichs, C. Dobbins, A. Hand, , N. P. King
This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.
bioRxiv · Mar 13, 2024Immunology
Y.-J. Park, D. Pinto, A. C. Walls, Z. Liu, A. De Marco, F. Benigni, F. Zatta, C. Silacci-Fregni, J. Bassi, K. R. Sprouse, A. Addetia, J. E. Bowen, C. Stewart, M. Giurdanella, C. Saliba, , Piccoli
This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.
bioRxiv · May 8, 2022Immunology
J. E. Bowen, K. R. Sprouse, A. C. Walls, I. G. Mazzitelli, J. K. Logue, N. M. Franko, K. Ahmed, A. Shariq, E. Cameroni, A. Gori, A. Bori, C. M. Posavad, J. M. Dan, Z. Zhang, D. Weiskopf, , D. Veesler
This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.
bioRxiv · Mar 15, 2022 · PreprintImmunology
A. C. Walls, L. A. VanBlargan, K. Wu, A. Choi, M. J. Navarro, D. Lee, L. Avena, D. M. Berrueta, M. N. Pham, S. Elbashir, M. C. Miranda, E. Kepl, M. Johnson, A. Blackstone, K. R. Sprouse, , D. Veesler
This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.
bioRxiv · Feb 7, 2022Immunology
J. E. Bowen, A. C. Walls, A. Joshi, K. R. Sprouse, C. Stewart, M. A. Tortorici, N. M. Franko, J. K. Logue, I. G. Mazzitelli, S. W. Tiles, K. Ahmed, A. Shariq, G. Snell, N. T. Iqbal, J. Geffner, , D. Veesler
This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.
bioRxiv · Dec 19, 2021 · PreprintImmunology
E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P
This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.
bioRxiv · Dec 12, 2021Immunology
A. C. Walls, K. R. Sprouse, A. Joshi, J. E. Bowen, N. Franko, M.-J. Navarro, C. Stewart, M. McCallum, E. A. Goecker, E. J. Degli-Angeli, J. Logue, A. Greninger, H. Chu, D. Veesler
The paper examines antibody responses in Delta breakthrough infections, finding they are more potent, durable, and broad compared to vaccinated-only or infected-only individuals.
bioRxiv · Dec 8, 2021 · PreprintImmunology
M. McCallum, A. C. Walls, K. R. Sprouse, J. E. Bowen, L. Rosen, H. V. Dang, A. deMarco, N. Franko, S. W. Tilles, J. Logue, M. C. Miranda, M. Ahlrichs, L. Carter, G. Snell, M. S. Pizzuto, , D. Veesler
This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.
bioRxiv · Aug 11, 2021Immunology